Performance of Cimetidine-corrected MDRD Equation in Renal Transplant Patients
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · May 16, 2007
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Kidney transplantation \> 1 year
- • Patient with immunosuppressant treatment of TACROLIMUS (PROGRAF)
- • Creatinine clearance \> 30 ml/min/1,73m2 within 3 months before inclusion
- • Written informed consent
- • Patient affiliated to social insurance
- Exclusion Criteria:
- • Unstable renal function defined by serum creatinine (J0) \> 25% serum creatinine realised in 3 months
- • Treatment: Bactrim, Fansidar, Cimetidine arrow within the week before inclusion
- • Contraindication listed in the labeling of Cimetidine arrow
- • Last residual rate of Tacrolimus \> 12 ng/ml.
- • Treatment : carvedilol, phenytoïn (interaction with cimetidine)
- • Serious hepatic insufficiency
About Centre Hospitalier Universitaire De Saint Etienne
The Centre Hospitalier Universitaire (CHU) de Saint-Étienne is a leading academic medical center in France, dedicated to advancing healthcare through innovative clinical research and high-quality patient care. With a robust infrastructure that supports a wide range of medical specialties, CHU de Saint-Étienne fosters collaboration between healthcare professionals, researchers, and academic institutions. The center is committed to conducting rigorous clinical trials that adhere to ethical standards and regulatory requirements, aiming to improve treatment outcomes and enhance the overall health of the community. Through its dedication to scientific excellence and patient-centered care, CHU de Saint-Étienne plays a pivotal role in the advancement of medical knowledge and the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Etienne, , France
Patients applied
Trial Officials
Christophe Mariat, MD PhD
Principal Investigator
CHU SAINT-ETIENNE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials